Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/101177
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Carda, José Pedro | - |
dc.contributor.author | Santos, Lurdes | - |
dc.contributor.author | Mariz, José Mário | - |
dc.contributor.author | Monteiro, Pedro | - |
dc.contributor.author | Gonçalves, Humberto Miguel | - |
dc.contributor.author | Raposo, João | - |
dc.contributor.author | Silva, Maria Gomes da | - |
dc.date.accessioned | 2022-08-16T08:52:46Z | - |
dc.date.available | 2022-08-16T08:52:46Z | - |
dc.date.issued | 2021-12 | - |
dc.identifier.issn | 1607-8454 | - |
dc.identifier.uri | https://hdl.handle.net/10316/101177 | - |
dc.description.abstract | Ibrutinib, a potent inhibitor of the Bruton tyrosine kinase, has revolutionized the treatment of many B-cell malignancies. Ibrutinib has an established favorable toxicity profile with up to 8 years of experience in clinical trials; however, despite ibrutinib's favorable toxicity profile, dose reductions and treatment discontinuations are becoming more evident in clinical practice, particularly in the setting of specific clinical contexts and patient characteristics. This manuscript is set to provide practical recommendations on the management of patients treated with this agent in daily practice. | pt |
dc.language.iso | eng | pt |
dc.relation | The project received financial support from Janssen for logistics of expert meetings and editorial support. | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt |
dc.subject | B-cell malignancies | pt |
dc.subject | Bruton tyrosine kinase inhibitor | pt |
dc.subject | ibrutinib | pt |
dc.subject | recommendations | pt |
dc.title | Management of ibrutinib treatment in patients with B-cell malignancies: clinical practice in Portugal and multidisciplinary recommendations | pt |
dc.type | article | pt |
degois.publication.firstPage | 785 | pt |
degois.publication.lastPage | 798 | pt |
degois.publication.issue | 1 | pt |
degois.publication.title | Hematology (United Kingdom) | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 1607-8454 | - |
dc.identifier.doi | 34605364 | - |
dc.identifier.doi | 10.1080/16078454.2021.1980690 | - |
dc.identifier.doi | 34605364 | - |
dc.identifier.doi | 1607-8454 | - |
degois.publication.volume | 26 | pt |
dc.date.embargo | 2021-12-01 | * |
dc.identifier.pmid | 34605364 | - |
uc.date.periodoEmbargo | 0 | pt |
dc.identifier.eissn | 1607-8454 | - |
item.grantfulltext | open | - |
item.cerifentitytype | Publications | - |
item.languageiso639-1 | en | - |
item.openairetype | article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | Com Texto completo | - |
Appears in Collections: | I&D ICBR - Artigos em Revistas Internacionais |
Files in This Item:
SCOPUSTM
Citations
1
checked on May 13, 2024
WEB OF SCIENCETM
Citations
1
checked on May 2, 2024
Page view(s)
58
checked on May 15, 2024
Download(s)
100
checked on May 15, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License